No, Farxiga (dapagliflozin) should NOT be added in a patient with end-stage renal disease (ESRD) on insulin.
Dapagliflozin is contraindicated for initiation in patients with end-stage renal disease, and the FDA label explicitly states it is not recommended for CKD treatment in patients requiring dialysis 1.
Why This Is Not Appropriate
FDA-Approved Limitations
The FDA label for Farxiga clearly states that initiation is not recommended with eGFR <20 mL/min/1.73 m² for the CKD indication 1. End-stage renal disease (ESRD), by definition, represents eGFR <15 mL/min/1.73 m² or patients on dialysis—well below this threshold.
Guideline Consensus
The 2022 KDIGO/ADA consensus guidelines specify that:
- SGLT2 inhibitors can be initiated in patients with eGFR ≥20 mL/min/1.73 m² 2
- For dapagliflozin specifically, initiation is not recommended with eGFR <25 mL/min/1.73 m², though it may be continued if already established and tolerated until dialysis is initiated 2
- The drug is not expected to be effective in ESRD based on its mechanism of action 1
Mechanism-Based Rationale
SGLT2 inhibitors work by blocking glucose reabsorption in the proximal renal tubule. In ESRD:
- There is minimal to no glomerular filtration
- The drug cannot reach its site of action effectively
- Glucose-lowering efficacy is essentially absent 2
- Even the cardiorenal protective benefits demonstrated in trials were in patients with higher eGFR levels 3, 4
Critical Safety Concerns in Insulin-Requiring Patients
Patients with type 2 diabetes requiring insulin are at particular risk for euglycemic diabetic ketoacidosis (DKA) when taking SGLT2 inhibitors 2. The guidelines explicitly state:
- Maintain at least low-dose insulin in insulin-requiring individuals on SGLT2i
- Institute sick day protocols
- Monitor for ketones in high-risk situations 2
In ESRD, this risk is compounded by:
- Altered insulin clearance requiring dose adjustments
- Unpredictable glycemic patterns
- Limited drug efficacy for glucose control
The Evidence Base
The landmark DAPA-CKD trial 3 that established dapagliflozin's renal benefits:
- Enrolled patients with eGFR 25-75 mL/min/1.73 m²
- Specifically excluded ESRD patients
- Showed benefits were maintained when eGFR declined below initiation thresholds only if already established on therapy
What to Do Instead
For glycemic control in ESRD patients on insulin:
- Optimize insulin regimen with conservative titration to avoid hypoglycemia 2
- Consider GLP-1 receptor agonists (dulaglutide, liraglutide, or semaglutide require no dose adjustment even in advanced CKD) 2
- Consider DPP-4 inhibitors with appropriate dose reductions (e.g., linagliptin requires no adjustment; sitagliptin maximum 25 mg daily) 2
- Avoid metformin (contraindicated with eGFR <30) 2
Key Pitfall to Avoid
Do not confuse "may continue until dialysis" with "may initiate in ESRD." The guidelines allow continuation of dapagliflozin if a patient was already on it and progresses to ESRD, but this is fundamentally different from starting it de novo in someone with established ESRD 2.